GWP.L Share News (GWP)

GW Pharma In US Offering Of American Depositary Shares (ALLISS)

GW Pharmaceuticals Gets Notice Of Allowance On Cannabidivarin Patent

GW Pharmaceuticals Says New Physician Report Data Supports Epidiolex

GW Pharmaceuticals Starts Second Phase III Trial For Epidiolex

BUZZ-GW Pharmaceuticals Plc: Data on epilepsy drug shows promise

** U.S.-listed shares of London-based maker of cannabis-based drugs up about 9 pct at $104.77 premarket ** Company's childhood epilepsy drug, epidiolex, currently in use through an expanded access program, showed marked improvement in median reduction of seizure frequency, data compiled by

GW Pharmaceuticals Says AAN Highlights Epidiolex In New Report

BUZZ-U.S. STOCKS ON THE MOVE-Rada Electronic, Intercept Pharma, Alon USA

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell on Tuesday in a modest retreat from the previous

BUZZ-U.S. STOCKS ON THE MOVE-Lorillard, Charter Communications, Synta Pharma

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell at the open on Tuesday, slightly reversing the pr

BUZZ-U.S. STOCKS ON THE MOVE-Conn's, Lorillard, GW Pharma, DryShips

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock were poised to open lower on Tuesday, indicating a mode

BUZZ-GW Pharma Plc: Commences trial to test cannabis-based drug in Dravet syndrome

** U.S.-listed shares of the maker of cannabis-based drugs up 4 pct at $91.99 premarket ** The UK-based company has started the second leg of a mid-stage trial testing Epidiolex to treat Dravet syndrome, a rare, treatment-resistant form of childhood epilepsy ** Data from the trial is

GW Pharmaceuticals Begins Phase III Epidiolex Trial In Dravet Syndrome

UK DIRECTOR DEALINGS SUMMARY: Scholium Team Buys After Profit Warning

DIRECTOR DEALINGS: GW Pharmaceuticals COO Sells 10,000 Shares

UK MORNING BRIEFING: BT Leads FTSE 100 On EE Deal Confirmation

UK AGM, EGM Calendar - Week Ahead